PubRank

Lourdes Valera

Author PubWeight™ 19.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010 2.50
2 Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012 2.29
3 Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011 2.10
4 Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother 2005 1.94
5 Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011 1.44
6 In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2012 1.17
7 Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 2013 1.11
8 Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012 1.09
9 In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 2011 1.05
10 In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. J Antimicrob Chemother 2002 0.95
11 Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles. J Virol 2012 0.92
12 A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir. J Virol Methods 2013 0.79
13 HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides. Bioorg Med Chem Lett 2012 0.78
14 HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity. J Med Chem 2013 0.77
15 HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies. Bioorg Med Chem Lett 2012 0.76
16 HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives. Bioorg Med Chem Lett 2013 0.75